GENFIT Seeks $132 Million IPO to Support NASH Programs

GENFIT Seeks $132 Million IPO to Support NASH Programs

Source: 
BioSpace
News Tags: 
snippet: 

France-based GENFIT launched its $132 million initial public offering plans in order to raise funds that will be used to support the Phase III trial and planned commercialization of its elafibranor compound for non-alcoholic steatohepatitis (NASH).